|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoietin (Epo) is used for the treatment of cancer‑associated anaemia.
|
30483799 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therapy (epoetin alfa) for the treatment of anemia in patients undergoing dialysis.
|
31340116 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoietin (EPO) is one of the most successful biopharmaceuticals in history and is used for treating anemia of different origins.
|
30964047 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
DKD-related anemia developed earlier and was more severe than non-DKD-related anemia based on more complicated mechanisms, including greater bleeding tendency associated with antiplatelet effect, less O2 sensing due to autonomic neuropathy or renin-angiotensin-aldosterone system inhibitor use, inhibitory effect of inflammatory cytokines, urinary loss of erythropoietin (EPO), and poor response to EPO.
|
31453863 |
2019 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Considering the importance of anemia in hemodialysis patients and its complications, in this study, the effect of erythropoietin administration on blood parameters by comparing the methods of subcutaneous and intravenous administrations was investigated.
|
30783118 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although the pathogenic mechanisms of anemia are multiple, erythropoietin deficiency appears as the dominant factor.
|
31412807 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
MIRCERA, a PEGylated recombinant erythropoietin (rhEPO) used in the treatment of anemia due to chronic kidney disease, has also been abused by athletes as performance-enhancing drug.
|
30426415 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Despite the widespread use of erythropoietin-stimulating agents (ESAs) to treat anemia in patients undergoing hemodialysis, the relative mortality risks associated with use of different types of ESAs are unknown.
|
31015255 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The use of erythropoiesis-stimulating agents has come under scrutiny after prospective clinical trials using recombinant erythropoietin to correct anemia reported increased incidence of thromboembolic events and cancer-related deaths.
|
30700319 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoiesis-stimulating agents (ESAs), such as erythropoietin (EPO) and darbepoetin, may alleviate anemia in diffuse large B-cell lymphoma (DLBCL) patients.
|
30973963 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta with those of the shorter-acting agents epoetin alfa/beta and darbepoetin alfa in patients with anemia of CKD.
|
31420350 |
2019 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Serum erythropoietin levels are lower than expected for degree of anemia.
|
31230731 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Disturbances in the physiological regulation of erythropoietin (EPO) in patients with sickle cell disease (SCD) may contribute to worsening anaemia and increased transfusion requirements, but the use of recombinant EPO in this group of patients is controversial.
|
30695814 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
O2 homeostasis is critically intertwined with erythropoietic response in blood loss and anemia and the hormones that modulate iron mobilization and RBC production (e.g., erythropoietin, erythroferrone, and hepcidin) are intriguing markers for the monitoring of transfusion effectiveness in acute and chronic settings.
|
31483333 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
EPO is usually to treat anemia in CKD and also improved in cognitive function.
|
31447360 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The efficacy and safety of molidustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, have been evaluated in three 16-week, phase 2b studies in patients with CKD and anemia who are not on dialysis (DaIly orAL treatment increasing endOGenoUs Erythropoietin [DIALOGUE] 1 and 2) and in those who are on dialysis (DIALOGUE 4).
|
30559105 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
In contrast, the TfC-bl/C-bl mice had elevated RBC counts and an exaggerated response to exogenous erythropoietin sufficient to ameliorate the anemia.
|
31434707 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has potential to treat anemia associated with CKD through increased erythropoietin production and improved iron availability.
|
31387097 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The present study revealed that TP0463518 specifically induced EPO production in the liver and improved anemia.
|
31585986 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Despite the wide use of EPO alfa in the treatment of anaemia in patients with MDS, the median response duration is approximately only 24 months.
|
31508719 |
2019 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Anemia was present in adenine-fed mice, while PBI-4050 blunted these effects and led to significantly higher plasma erythropoietin (EPO) levels.
|
31308217 |
2019 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that trauma plasma would increase bone marrow stromal fibroblast expression of interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), stem cell factor (SCF), and activation of nuclear factor kappa-light-chain-enhancer of activated B cells and correlate with injury severity and anemia.
|
31207479 |
2019 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Anemia is a well-known complication of advanced CKD and treatment with erythropoietin analogues (epoetin) remains a key component of management.
|
31477257 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Biologics are widely used to manage the side effects of cancer treatment (e.g., epoetin alfa is used to treat chemotherapy-induced anemia [CIA] and granulocyte colony-stimulating factors [G-CSFs] are used to treat chemotherapy-induced neutropenia [CIN]).
|
31161461 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Highlights Few comparative data have explored the costs and potential savings of using long-acting erythropoietin-stimulating agents (ESA) instead of short-acting ESAs to treat anemia in CKD patients on hemodialysis.
|
30915883 |
2019 |